Skip to main content


HCV and cancer collection: call for papers

Guest edited by: Dr Stefano Vella

2014 was an important year for scientists working on Hepatitis C Virus (HCV) as it celebrated the 25th anniversary of its discovery and the establishment of new Interferon (IFN)-free therapeutic regimens able to eradicate HCV infections. HCV isolation was achieved in Dr Houghton’s laboratory at Chiron Corporation in 1989, almost 20 years after the demonstration by Alter’s Laboratory at the NIH that most post-transfusion hepatitis cases were not due to hepatitis A or B viruses.

25 years later, more than 130 million HCV-infected people at high risk of morbidity (including progression to hepatocellular carcinoma (HCC)), the fifth most prevalent cancer type worldwide and the third cause of cancer deaths) and mortality (around 500,000 deaths per year are attributed to the virus), finally have a chance of an effective cure. The current studies will likely contribute to the final eradication of the virus and to effective treatment of HCV-related disease as well as prevention of progression to HCC, by identification of specific pathways and novel molecular/immunotherapy targets.

The collection welcomes articles on all HCV-related topics, in particular:

  • Clinical and preclinical studies relevant to identify regimen and demonstrate effectiveness of the new antiviral treatment for their worldwide implementation and HCV eradication
  • Immunology, molecular and systems biology studies aimed at early diagnosis and innovative treatment of HCV-related disease in order to mitigate their huge death burden
  • Epidemiological and biomolecular studies on the role of HCV in HCC pathogenesis

Please submit your manuscript online, stating in your cover letter that your submission is intended for the HCV and cancer collection.

View all collections in Infectious Agents and Cancer.

  1. Research Article

    Safety of new DAAs for chronic HCV infection in a real life experience: role of a surveillance network based on clinician and hospital pharmacist

    Direct Antiviral Agents (DAAs) for HCV therapy represents a step ahead in the cure of chronic hepatitis C. Notwithstanding the promising results in several clinical trials, few data are available on adverse ef...

    A. Nappi, A. Perrella, P. Bellopede, A. Lanza, A. Izzi, M. Spatarella and C. Sbreglia

    Infectious Agents and Cancer 2017 12:12

    Published on: 7 February 2017

  2. Review

    Systemic manifestations of hepatitis C infection

    Chronic hepatitis C (HCV) is a common infection affecting 185 million people worldwide. The most common manifestation of chronic HCV is progressive liver fibrosis, cirrhosis, liver failure and hepatocellular c...

    Lydia Tang, Lauren Marcell and Shyam Kottilil

    Infectious Agents and Cancer 2016 11:29

    Published on: 23 May 2016